Neuroleptic Malignant Syndrome Linked to Polypharmacy, Benzos, and Race


Research from London and Taipei finds that neuroleptic malignant syndrome (NMS) is associated with the number of different antipsychotics used (polypharmacy), rather than the overall dose. The researchers also found an association between NMS and Haldol, Abilify, benzodiazepines, and depot flupentixol.  A correlation between NMS and non-white ethnicity was also found.

Abstract →

Su, Y., Chang, C., Hayes, R., Harrison, S.; Retrospective chart review on exposure to psychotropic medications associated with neuroleptic malignant syndrome. Acta Psychiatrica Scandinavica. Online November 15, 2013. DOI: 10.1111/acps.12222

Previous articleChildhood Social Function & Schizophrenia
Next articleSleep Therapy for Depression
Kermit Cole
Kermit Cole, MFT, founding editor of Mad in America, works in Santa Fe, New Mexico as a couples and family therapist. Inspired by Open Dialogue, he works as part of a team and consults with couples and families that have members identified as patients. His work in residential treatment — largely with severely traumatized and/or "psychotic" clients — led to an appreciation of the power and beauty of systemic philosophy and practice, as the alternative to the prevailing focus on individual pathology. A former film-maker, he has undergraduate and master's degrees in psychology from Harvard University, as well as an MFT degree from the Council for Relationships in Philadelphia. He is a doctoral candidate with the Taos Institute and the Free University of Brussels. You can reach him at [email protected].